"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. Relapsing Neuromyelitis Optica Spectrum Disorder - Overview
3. Executive Summary
4. Relapsing Neuromyelitis Optica Spectrum Disorder: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Relapsing Neuromyelitis Optica Spectrum Disorder: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. Inebilizumab – Viela Bio
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. MEDI-551 – MedImmune LLC
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. Satralizumab – F. Hoffmann-La Roche Ltd
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. Relapsing Neuromyelitis Optica Spectrum Disorder: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. Relapsing Neuromyelitis Optica Spectrum Disorder: Additional Key Insights
7.1. Epidemiology Overview: Relapsing Neuromyelitis Optica Spectrum Disorder
7.2. Current Market Scenario: Relapsing Neuromyelitis Optica Spectrum Disorder Therapeutics
8. Relapsing Neuromyelitis Optica Spectrum Disorder: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.